Clerio Vision takes a step past LASIK (podcast)

Clerio Visio CEO, Mikael Totterman
Clerio Visio CEO, Mikael Totterman

Clerio Vision is developing a non-invasive, tissue-sparing laser technology that corrects vision by modifying the reactive index of the cornea. It’s the third med-tech spinout from the University of Rochester for CEO Mikael Totterman and is starting to get some press, including this BioTuesdays piece. I’m on the company’s board of directors.

I caught up with Mikael recently to discuss the company’s progress.

  • (0:20) Clerio is developing a laser technology for refractive eye surgery. We already have LASIK. Do we need another approach?
  • (2:44) So LASIK has downsides, but you also use lasers. What’s the difference?
  • (3:35) How do you test something like this? What testing has been done?
  • (4:51) If the technology is so promising, why did Bausch & Lomb stop development?
  • (6:30) What steps have you taken with the company since its founding?
  • (7:55) When can we expect to see a product on the market?
  • (8:56) This is at least the third company you’ve spun out of U of R. What is the biggest lesson that you learned and how are you applying these insights to Clerio?
  • (11:00) What sort of development costs are required for commercialization? How are you funded?
  • (12:08) What else should I know?
  • (13:25) When you make modifications to intraocular lenses for cataracts, do you do it before or after implantation?

By healthcare business consultant David E. Williams, president of Health Business Group.

 

 

November 2, 2015

Leave a Reply

Your email address will not be published. Required fields are marked *